Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Tennessee: - Memorial Hospital — Chattanooga, Tennessee
- Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
- Pulmonary Medicine Center of Chattanooga-Hixson — Hixson, Tennessee
- Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
- Baptist Memorial Hospital for Women — Memphis, Tennessee
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Tennessee: - Vanderbilt Breast Center at One Hundred Oaks — Nashville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Tennessee: - East Tennessee Childrens Hospital — Knoxville, Tennessee
- Saint Jude Children's Research Hospital — Memphis, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Tennessee: - Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Tennessee: - Saint Jude Children's Research Hospital — Memphis, Tennessee
- The Children's Hospital at TriStar Centennial — Nashville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Tennessee: - East Tennessee Childrens Hospital — Knoxville, Tennessee
- Saint Jude Children's Research Hospital — Memphis, Tennessee
- The Children's Hospital at TriStar Centennial — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Tennessee: - Saint Jude Children's Research Hospital — Memphis, Tennessee
Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT06701812
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee
Phase 2 Recruiting Academic/Other
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT05535166
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population i…
Sponsor: LigaChem Biosciences, Inc.
NCT ID: NCT05941507
Sites in Tennessee: - Tennessee Oncology — Nashville, Tennessee
Phase 2 Recruiting Industry
This study consists of 2 portions. The phase 2 portion is an open-label, single-arm study to evaluate the safety and efficacy of NAI, PD-L1 t-haNK, and bevacizumab combination therapy in participants with recurrent or progressive GBM. The …
Sponsor: ImmunityBio, Inc.
NCT ID: NCT06061809
Sites in Tennessee: - Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Academic/Other
This is an open-label, multi-center, Phase 1/2 study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT04923126
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 2 Recruiting Academic/Other
This clinical trial tests how well entrectinib works to treat patients less than 3 years of age with NTRK 1/2/3 or ROS1 fused, high grade glioma or other central nervous system (CNS) tumors.
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT06528691
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 1 Recruiting Industry
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is …
Sponsor: Pfizer
NCT ID: NCT05355701
Sites in Tennessee: - Sarah Cannon Research Institute - Pharmacy — Nashville, Tennessee
- SCRI Oncology Partners — Nashville, Tennessee
- TriStar Bone Marrow Transplant — Nashville, Tennessee
- TriStar Centennial Medical Center - Cell Processing Lab — Nashville, Tennessee
- TriStar Centennial Medical center — Nashville, Tennessee
Phase 1 Recruiting Network
This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or…
Sponsor: Children's Oncology Group
NCT ID: NCT06894979
Sites in Tennessee: - Saint Jude Children's Research Hospital — Memphis, Tennessee
Phase 1 Recruiting Industry
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after stand…
Sponsor: RasCal Therapeutics, Inc.
NCT ID: NCT04678648
Sites in Tennessee: - Sarah Cannon, SCRI Oncology Partners — Nashville, Tennessee
Phase 1 Recruiting Academic/Other
Loc3CAR is a Phase I clinical trial evaluating the use of autologous B7-H3-CAR T cells for participants ≤ 21 years old with primary CNS neoplasms. B7-H3-CAR T cells will be locoregionally administered via a CNS reservoir catheter. Study pa…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT05835687
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
EARLY Phase 1 Recruiting Academic/Other
High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown promise, but its efficacy remains variable and poorly understood in this patien…
Sponsor: Eben Rosenthal
NCT ID: NCT07210632
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Tennessee: - Massive Bio SYNERGY-AI site — Memphis, Tennessee
- Massive Bio SYNERGY-AI site — Nashville, Tennessee
Phase 4 Recruiting Industry
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT03975829
Sites in Tennessee: - St Jude Childrens Research Hospital — Memphis, Tennessee
NA Recruiting Academic/Other
Low-grade gliomas (LGGs) are the most common brain tumors in children, and a subset of these tumors are treated definitively with focal radiation therapy (RT). These patients often survive for many years after receiving RT and experience l…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT04065776
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
NA Recruiting Academic/Other
The objective of this study is to estimate the feasibility and acceptability of cognitive training in the virtual reality setting with children undergoing radiotherapy for brain tumors. To achieve this goal, the investigators plan to study…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT05947045
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Recruiting Academic/Other
The study is being done to learn more about the long-term health and well-being of participants treated for medulloblastoma. The study is to decide which evaluations focusing on therapy-related lasting effects (or toxicities) should be con…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT07085325
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee